Using ctDNA Blood Test to Screen for Cancer DNA after Treatment for Early-Stage TNBC and/or an Inherited or Tumor BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)
https://www.facingourrisk.org/research-clinical-trials/study/170 /screening-for-cancer-dna-in-the-blood-after-treatment-for-early-stage-tnbc-andor-a-brca-mutation-followed-by-study-comparing-niraparib-with-placebo-for-people-with-cancer-dna-found-in-their-blood-zest
Clinicaltrials.gov identifier:
NCT04915755 (https://clinicaltrials.gov/show/NCT04915755)
Early-stage TNBC or early-stage breast cancer with a BRCA mutation
About the Study
The ZEST study has two parts, a screening portion that will look for evidence of cancer cell DNA in the bloodstream, and an intervention portion that is open to people who test positive for cancer cell DNA in their bloodstream.
Note: This study is no longer enrolling.
This Study is Open To:
NOTE: This study is closed.
This Study is Not Open To:
NOTE: This study is closed.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.